Ascendis Pharma

罗森律师事务所宣布一项代表Ascendis Pharma (NASDAQ: ASND) 的投资人对该公司潜在的集体诉讼请求发起调查。该调查缘起于对Ascendis 可能向投资公众发布了具有重大误导性的商业信息的指控。

如果您购买了Ascendis 股票,并且您想参加此次集体诉讼的话,请点击“加入此集体行动”键。


如果您购买了 Ascendis 证券,您可能有权获得赔偿,而无需支付任何自付费用或通过应急费用安排产生的费用。

Details of investigation:

2023 年 4 月 3 日盘前,Ascendis 宣布,“美国食物及药物监督管理局(“FDA”)已通知公司,在其正在进行的审查过程中,发现公司针对 TransCon PTH (palopegteriparatide) 治疗甲状旁腺功能减退症的新药申请(“NDA”)存在缺陷,目前其无法就标示和上市后要求/承诺进行进一步讨论。信中没有披露这些缺陷。”

受此消息影响,Ascendis 的美国存托股份(“ADS”)价格在 2023 年 4 月 3 日当天交易中下跌了 34.71%,开盘价为 67.12 美元。


Follow us on:
Company Name: Ascendis Pharma
Stock Symbol: ASND
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top